Medical Therapy. Adverse Effects or Lack of Adverse Effects

Acute Pulmonary Vasodilator Testing and Long-Term Clinical Course in Segmental Pulmonary Vascular Disease

Liezl Domingo, H. Sonali Magdo, Ronald W. DayUniversity of Utah and Primary Children’s Hospital.United States Pediatric CardiologyPediatr Cardiol 2018; 39: 501-508DOI: 10.1007/s00246-017-1780-9 AbstractResults of acute pulmonary vasodilator testing (AVT) and the outcome of medical therapy have not been described in patients with segmental pulmonary vascular disease (SPVD). We sought to compare the pulmonary vasodilatory effects of […]

Acute Pulmonary Vasodilator Testing and Long-Term Clinical Course in Segmental Pulmonary Vascular Disease Read More »

Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom

Andrew Constantine, Robert M. R. Tulloh, Konstantinos Dimopoulos, Petra Jenkins, Robin Condliffe, Katrijn Jansen, Natali A. Y. Chung, James Oliver, Helen Parry, Samantha Fitzsimmons, Niki Walker, Stephen John Wort, Vasilios Papaioannou, Kate von Klemperer, Paul CliftRoyal Brompton HospitalRoyal Brompton and Harefield Hospitals. Imperial College London. Liverpool Heart and Chest Hospital. University Hospital Bristol. Royal Hallamshire

Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom Read More »

Effects of Inhaled Iloprost for the Management of Persistent Pulmonary Hypertension of the Newborn

Sourabh Verma, Rishi Lumba, Sadaf H. Kazmi, Michelle J. Vaz, Shrawani Soorneela Prakash, Sean M. Bailey, Pradeep V. Mally, Tara M. RandisNYU Grossman School of Medicine. University of South Florida. United States American Journal of PerinatologyAm J Perinatol 2022; 39: 1441-1448DOI: 10.1055/s-0040-1722653 AbstractObjective: The study aimed to evaluate the effects of inhaled iloprost on oxygenation indices in

Effects of Inhaled Iloprost for the Management of Persistent Pulmonary Hypertension of the Newborn Read More »

Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial

Safaa S. Iman, Rania A. El-Farrash, Amr S. Taha, Ghada A. SalehAin Shams University and Cairo Ministry of Health.Egypt Journal of Cardiovascular PharmacologyJ Cardiovasc Pharmacol 2022; 80: 746-752DOI: 10.1097/FJC.0000000000001332 AbstractPersistent pulmonary hypertension of the newborn (PPHN) is a condition caused by failure of pulmonary vascular adaptation at birth, resulting in severe hypoxia. Several therapeutic modalities are

Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial Read More »

Neonatal pulmonary hypertension after severe early-onset fetal growth restriction: post hoc reflections on the Dutch STRIDER study

Anouk Pels, Wes Onland, Rolf M. F. Berger, Arno F. J. van Heijst, Enrico Lopriore, Irwin K. M. Reiss, Jacqueline Limpens, Sanne J. Gordijn, Wessel GanzevoortUniversity of Amsterdam and Emma Children’s Hospital. University of Groningen, University Medical Center Groningen and Beatrix Children’s Hospital. Radboud University Medical Center and Amalia Children’s Hospital. Leiden University Medical Center. Erasmus University Medical Center. Netherlands European Journal of PediatricsEur J Pediatr 2022; 181: 1709-1718DOI: 10.1007/s00431-021-04355-x AbstractThe aim was

Neonatal pulmonary hypertension after severe early-onset fetal growth restriction: post hoc reflections on the Dutch STRIDER study Read More »

Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial

Christine M. Pierce, Min H. Zhang, Baldvin Jonsson, Dinu Iorga, Narayan Cheruvu, Cecile C. Balagtas, Robin H. SteinhornGreat Ormond Street Hospital for Children. Pfizer Inc. Karolinska Institute and University Hospital. Rady Children’s Hospital and University of California San Diego.United States Journal of PediatricsJ Pediatr 2021; 237: 154-161DOI: 10.1016/j.jpeds.2021.05.051 AbstractObjective: To investigate the efficacy and safety of sildenafil

Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial Read More »

Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension

Shinichi Takatsuki, Tomotaka Nakayama, Yurika Shimizu, Reiko Kawai, Hiroyuki MatsuuraToho University Omori Medical Center. Kochi Medical School Hospital.Japan Cardiology in the YoungCardiol Young 2023; 33: 196-200DOI: 10.1017/S1047951122000415 AbstractObjective: This study aimed to investigate the safety, tolerability, and efficacy of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.Methods: This retrospective cohort study included clinical

Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension Read More »

Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy

Regan E. Geisinger, Amy H. Stanford, Brady Thomas, Steven H. Abman, Patrick J. McNammaraUniversity of Iowa. University of Colorado.United States Journal of PediatricsJ Pediatr 2022; DOI: 10.1016/j.jpeds.2022.11.026 AbstractThe effects of riociguat, an oral-soluble guanylate-cyclase stimulator, were studied in 10 infants with chronic pulmonary arterial hypertension. Respiratory status (n = 8/10), right heart dilation (n = 7/10),

Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy Read More »

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study

Humberto García Aguilar, Matthias Gorenflo, D. Dunbar Ivy, Shahin Moledina, Biagio Castaldi, Hidekazu Ishida, Paweł Cześniewicz, Jacek Kusa, Oliver Miera, Joseph Pattathu, Ken‐Pen Weng, Laszlo Ablonczy, Christian Apitz, Marta Katona, Kenichi Kurosaki, Tomas Pulido, Hiroyuki Yamagishi, Kazushi Yasuda, Galia Cisternas, Melanie Goth, Susanne Lippert, Anna Radomskyj, Soundos Saleh, Stefan Willmann, Gabriela Wirsching, Damien Bonnet, Maurice

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study Read More »

Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience

Azadeh Issapour, Benjamin Frank, Sarah Crook, Michelle D. Hite, Michelle L. Dorn, Erika B. Rosenzweig, D. Dunbar Ivy, Usha S. KrishnanColumbia University Irving Medical Center. University of Colorado and Children’s Hospital Colorado.United States Pediatric PulmonologyPediatr Pulmonol 2022; 57: 724-733DOI: 10.1002/ppul.25796 AbstractObjective: To describe the safety and tolerability of treatment with ambrisentan and tadalafil in pediatric pulmonary hypertension

Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience Read More »

Scroll to Top